The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“This appears to mimic regulatory phosphorylation, increasing BRAF activity approximately 10-fold compared with wild-type [12].”
BackgroundComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 1×
“been observed in all four subtypes [78].”
Self-citationK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“However, there are mutations that confer resistance to these therapies such as KRAS [13, 14].”
BackgroundInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Self-citationUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Weisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1834 · Cited by 1,990
Molecular Genetics of Colorectal Cancer
Fearon, E. R. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130235 · Cited by 1,805
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · cited 3×
“7%), myalgia, dry skin (44%) Myalgia (11%), vomiting, arthralgia and insomnia (5%) Doublet BRAF þ EGFR Vemurafenib þ cetuximab [52] 4 3.”
BackgroundMethodSelf-citationWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“For instance, no responses were observed in BRAF-mt mCRC patients who were treated with cetuximab-irinotecan [37] or cetuximab or panitumumab [38].”
BackgroundRoth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092 · cited 1×
“However, these results could not be confirmed in TRIBE phase III (study that compared FOLFOXIRI-Beva against FOLFIRI-Beva as upfront therapy mCRC) despite [36].”
ResultCorcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S. L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60613-2 · Cited by 960
The role of BRAF V600 mutation in melanoma
Ascierto, P. A., Kirkwood, J. M., Grob, J.-J., Simeone, E., Grimaldi, A. M., Maio, M., Palmieri, G., Testori, A., Marincola, F. M., & Mozzillo, N. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-85 · Cited by 801
Tran, B., Kopetz, S., Tie, J., Gibbs, P., Jiang, Z., Lieu, C. H., Agarwal, A., Maru, D. M., Sieber, O., & Desai, J. (2011) · Cancer · doi:10.1002/cncr.26086 · Cited by 797
Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., Kaplan, R., Quirke, P., Seymour, M. T., Richman, S. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0332 · Cited by 772
Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers
Samowitz, W. S., Sweeney, C., Herrick, J., Albertsen, H., Levin, T. R., Murtaugh, M. A., Wolff, R. K., & Slattery, M. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0404 · Cited by 737
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697 · cited 1×
“[50] led one of the first approaches with a BRAF inhibitor in previously-treated BRAF-mt mCRC, using the recommended phase II dose of vemurafenib for melanoma (960 mg b.”
MethodConvergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588 · cited 1×
“As said before, Alpelisib is an alpha-PI3K inhibitor, drug that has demonstrated to be ineffective in inhibiting PI3K pathway signaling in the presence of molecular alterations leading to PTEN loss of function [71].”
BackgroundBokemeyer, C., Cutsem, E. V., Rougier, P., Ciardiello, F., Heeger, S., Schlichting, M., Celik, I., & Köhne, C.-H. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.057 · Cited by 585
Loupakis, F., Ruzzo, A., Cremolini, C., Vincenzi, B., Salvatore, L., Santini, D., Masi, G., Stasi, I., Canestrari, E., Rulli, E., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605177 · Cited by 564
Richman, S. D., Seymour, M. T., Chambers, P., Elliott, F., Daly, C. L., Meade, A. M., Taylor, G., Barrett, J. H., & Quirke, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4295 · Cited by 560
Tveit, K. M., Guren, T., Glimelius, B., Pfeiffer, P., Sorbye, H., Pyrhonen, S., Sigurdsson, F., Kure, E., Ikdahl, T., Skovlund, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0915 · Cited by 533
Corcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2471 · Cited by 507
Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486
BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
Cantwell-Dorris, E. R., O'Leary, J. J., & Sheils, O. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0799 · Cited by 459
Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
Lochhead, P., Kuchiba, A., Imamura, Y., Liao, X., Yamauchi, M., Nishihara, R., Qian, Z. R., Morikawa, T., Shen, J., Meyerhardt, J. A., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt173 · Cited by 442
Deng, G., Bell, I., Crawley, S., Gum, J., Terdiman, J. P., Allen, B. A., Truta, B., Sleisenger, M. H., & Kim, Y. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1118-3 · Cited by 409
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
Yokota, T., Ura, T., Shibata, N., Takahari, D., Shitara, K., Nomura, M., Kondo, C., Mizota, A., Utsunomiya, S., Muro, K., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.19 · Cited by 401
Kopetz, S., Guthrie, K. A., Morris, V. K., Lenz, H.-J., Magliocco, A. M., Maru, D., Yan, Y., Lanman, R., Manyam, G., Hong, D. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01994 · Cited by 389
Seymour, M. T., Brown, S. R., Middleton, G., Maughan, T., Richman, S., Gwyther, S., Lowe, C., Seligmann, J. F., Wadsley, J., Maisey, N., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70163-3 · Cited by 388
Ahronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1518 · Cited by 322
Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.173 · Cited by 319
Souglakos, J., Philips, J., Wang, R., Marwah, S., Silver, M., Tzardi, M., Silver, J., Ogino, S., Hooshmand, S., Kwak, E., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605164 · Cited by 310
Mao, M., Tian, F., Mariadason, J. M., Tsao, C. C., Lemos, R., Dayyani, F., Gopal, Y. N. V., Jiang, Z.-Q., Wistuba, I. I., Tang, X. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1446 · Cited by 290 · cited 1×
“Furthermore, activation of the PI3K/AKT pathway has also been hypothesized to explain resistance to BRAF inhibitors in BRAFmt CRC cells [55].”
BackgroundSinicrope, F. A., Mahoney, M. R., Smyrk, T. C., Thibodeau, S. N., Warren, R. S., Bertagnolli, M. M., Nelson, G. D., Goldberg, R. M., Sargent, D. J., & Alberts, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.9591 · Cited by 279
Yaeger, R., Cercek, A., O'Reilly, E. M., Reidy, D. L., Kemeny, N., Wolinsky, T., Capanu, M., Gollub, M. J., Rosen, N., Berger, M. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2779 · Cited by 276
Fariña-Sarasqueta, A., van Lijnschoten, G., Moerland, E., Creemers, G.-J., Lemmens, V. E. P. P., Rutten, H. J. T., & van den Brule, A. J. C. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq258 · Cited by 263
Ogino, S., Brahmandam, M., Cantor, M., Namgyal, C., Kawasaki, T., Kirkner, G., Meyerhardt, J. A., Loda, M., & Fuchs, C. S. (2006) · Modern Pathology · doi:10.1038/modpathol.3800482 · Cited by 252
Peeters, M., Oliner, K. S., Parker, A., Siena, S., Van Cutsem, E., Huang, J., Humblet, Y., Van Laethem, J.-L., André, T., Wiezorek, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1913 · Cited by 243
Identification of a Poor-Prognosis BRAF-Mutant–Like Population of Patients With Colon Cancer
Popovici, V., Budinska, E., Tejpar, S., Weinrich, S., Estrella, H., Hodgson, G., Van Cutsem, E., Xie, T., Bosman, F. T., Roth, A. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5814 · Cited by 236
van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0795 · Cited by 232
Self-citationBRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Barras, D., Missiaglia, E., Wirapati, P., Sieber, O. M., Jorissen, R. N., Love, C., Molloy, P. L., Jones, I. T., McLaughlin, S., Gibbs, P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0140 · Cited by 230
Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.325 · Cited by 229
Tie, J., Gibbs, P., Lipton, L., Christie, M., Jorissen, R. N., Burgess, A. W., Croxford, M., Jones, I., Langland, R., Kosmider, S., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25555 · Cited by 227
Hong, D. S., Morris, V. K., El Osta, B., Sorokin, A. V., Janku, F., Fu, S., Overman, M. J., Piha-Paul, S., Subbiah, V., Kee, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0050 · Cited by 219
Rad, R., Cadiñanos, J., Rad, L., Varela, I., Strong, A., Kriegl, L., Constantino-Casas, F., Eser, S., Hieber, M., Seidler, B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.014 · Cited by 216
Yang, H., Higgins, B., Kolinsky, K., Packman, K., Bradley, W. D., Lee, R. J., Schostack, K., Simcox, M. E., Kopetz, S., Heimbrook, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2941 · Cited by 216 · cited 1×
“[72], published preclinical data from BRAF V600E-mt CRC cell lines and xenografts evaluating combinations of vemurafenib with different therapies including capecitabine, bevacizumab, irinotecan, erlotinib and cetuximab.”
BackgroundThe c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
Yaeger, R., Cercek, A., Chou, J. F., Sylvester, B. E., Kemeny, N. E., Hechtman, J. F., Ladanyi, M., Rosen, N., Weiser, M. R., Capanu, M., et al. (2014) · Cancer · doi:10.1002/cncr.28729 · Cited by 203
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
Loupakis, F., Cremolini, C., Salvatore, L., Masi, G., Sensi, E., Schirripa, M., Michelucci, A., Pfanner, E., Brunetti, I., Lupi, C., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.024 · Cited by 186
Cremolini, C., Bartolomeo, M. D., Amatu, A., Antoniotti, C., Moretto, R., Berenato, R., Perrone, F., Tamborini, E., Aprile, G., Lonardi, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv290 · Cited by 173
Schirripa, M., Bergamo, F., Cremolini, C., Casagrande, M., Lonardi, S., Aprile, G., Yang, D., Marmorino, F., Pasquini, G., Sensi, E., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.142 · Cited by 172
Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147
Gonsalves, W. I., Mahoney, M. R., Sargent, D. J., Nelson, G. D., Alberts, S. R., Sinicrope, F. A., Goldberg, R. M., Limburg, P. J., Thibodeau, S. N., Grothey, A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju106 · Cited by 170
Krejci, P., Aklian, A., Kaucka, M., Sevcikova, E., Prochazkova, J., Masek, J. K., Mikolka, P., Pospisilova, T., Spoustova, T., Weis, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035826 · Cited by 169
Clancy, C., Burke, J. P., Kalady, M. F., & Coffey, J. C. (2013) · Colorectal Disease · doi:10.1111/codi.12427 · Cited by 165
Seligmann, J. F., Fisher, D., Smith, C. G., Richman, S. D., Elliott, F., Brown, S., Adams, R., Maughan, T., Quirke, P., Cheadle, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw645 · Cited by 165
Karapetis, C. S., Jonker, D., Daneshmand, M., Hanson, J. E., O'Callaghan, C. J., Marginean, C., Zalcberg, J. R., Simes, J., Moore, M. J., Tebbutt, N. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0606 · Cited by 159
Morris, V., Overman, M. J., Jiang, Z.-Q., Garrett, C., Agarwal, S., Eng, C., Kee, B., Fogelman, D., Dasari, A., Wolff, R., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.06.001 · Cited by 132
Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns
Lea, I. A., Jackson, M. A., Li, X., Bailey, S., Peddada, S. D., & Dunnick, J. K. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm176 · Cited by 129
Oddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0396 · Cited by 121
Self-citationSmith, C. G., Fisher, D. J., Claes, B., Maughan, T., Idziaszczyk, S., Peuteman, G., Harris, R., James, M. D., Meade, A. M., Jasani, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2581 · Cited by 110
Pietrantonio, F., Oddo, D., Gloghini, A., Valtorta, E., Berenato, R., Barault, L., Caporale, M., Busico, A., Morano, F., Gualeni, A. V., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0297 · Cited by 103
Tabernero, J. M., van Geel, R. M. J. M., Guren, T. K., Yaeger, R. D., Spreafico, A., Faris, J. E., Yoshino, T., Yamada, Y., Kim, T. W., Bendell, J. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3544 · Cited by 99
Self-citationStintzing, S., Jung, A., Rossius, L., Modest, D. P., von Weikersthal, L. F., Decker, T. W., Kiani, A., Al‐Batran, S., Vehling‐Kaiser, U., Heintges, T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.445 · Cited by 97
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility
Vecchione, L., Gambino, V., Raaijmakers, J. A., Schlicker, A., Fumagalli, A., Russo, M., Villanueva, A., Beerling, E., Bartolini, A., Molleví, D. G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.059 · Cited by 91
Renaud, S., Romain, B., Falcoz, P., Olland, A., Santelmo, N., Brigand, C., Rohr, S., Guénot, D., & Massard, G. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.499 · Cited by 90
Naguib, A., Mitrou, P. N., Gay, L. J., Cooke, J. C., Luben, R., Ball, R. Y., McTaggart, A., Arends, M. J., & Rodwell, S. A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-99 · Cited by 70
Atreya, C. E., Cutsem, E. V., Bendell, J. C., André, T., Schellens, J. H. M., Gordon, M. S., McRee, A. J., O'Dwyer, P. J., Muro, K., Tabernero, J. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.103 · Cited by 62
Self-citationGomez‐Roca, C., Delord, J., Robert, C., Hidalgo, M. M., von Moos, R., Arance, A. M., Élez, E., Michel, D., Seroutou, A., Demuth, T., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu333.38 · Cited by 52
Self-citationCorcoran, R. B., André, T., Yoshino, T., Bendell, J. C., Atreya, C. E., Schellens, J. H. M., Ducreux, M. P., McRee, A. J., Siena, S., Middleton, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw370.04 · Cited by 46
Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A. M. R., Sobrero, A. F., Ducreux, M. P., Hotko, Y., André, T., Chan, E. W., Lordick, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3568 · Cited by 37
Cutsem, E. V., Atreya, C. E., André, T., Bendell, J. C., Schellens, J. H. M., Gordon, M. S., McRee, A. J., Yoshino, T., Muro, K., O'Dwyer, P. J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv262.07 · Cited by 23
Self-citationÉlez, E., Schellens, J. H. M., van Geel, R. M. J. M., Bendell, J. C., Spreafico, A., Schüler, M., Yoshino, T., Delord, J., Yamada, Y., Lolkema, M. P., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv262.08 · Cited by 15
Self-citationDrug Combo Beneficial in Colorectal Cancer
(2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2014-186 · Cited by 4
Cited by
Genetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
Piawah, S., & Venook, A. P. (2019) · Cancer · doi:10.1002/cncr.32163 · Cited by 488
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Spaander, M. C. W., Zauber, A. G., Syngal, S., Blaser, M. J., Sung, J. J., You, Y. N., & Kuipers, E. J. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00432-7 · Cited by 288
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
Metadata
- Authors
- Sanz-Garcia, E., Argiles, G., Elez, E., & Tabernero, J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 28
- Issue
- 11
- Pages
- 2648-2657
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2736345028
- Cited by
- 302
- References
- 81
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.